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Abstract 
BACKGROUND AND AIM: The aim of this study was to systematically analyze the effect of levamisole on treatment of 
recurrent aphthous stomatitis (RAS). 
METHODS: An electronic search was executed in PubMed, Cochrane, and Scopus after determining the research 
question using the appropriate Medical Subject Heading (MeSH) term covering the period from 1975 to 2015. 
Additional publications from hand searching and the reference section of each relevant article enriched the article list. 
Finally, 9 articles that have assessed the effect of levamisole on the treatment of RAS and had suitable qualifications for 
the accomplishment of systematic review and meta-analysis were included. 
RESULTS: The results showed that the chance of improvement in patients taking levamisole was 6 [odds ratio (OR) = 
5.67, 95% confidence interval (CI)] times more than in patients not taking this drug. 
CONCLUSION: It appears that levamisole is an effective drug for the treatment of RAS, but further appropriate studies 
should carryout in this context. 
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ecurrent aphthous stomatitis (RAS) 
is the most common type of an 
inflammatory lesion of the oral 
cavity, affecting 5-25% of the 
general population.1,2 The most characteristic 
symptom of the disease is the recurrent onset 
of single or multiple painful rounded or oval 
ulcers that appear mainly on non-keratinized 
oral mucosa of the lips, cheeks, and tongue.1 
The etiology of RAS remains unknown.1-3 
The suggested triggering factors include 
genetic predisposition, infection with 
microorganisms, food allergies, vitamin and 
microelement deficiencies, increased 
oxidative stresses, endocrine alterations 
(menstrual cycle), smoking cessation, certain 
chemical products, mechanical injuries, and 
anxiety.1,2,4 Immune changes occur in RAS, 
beginning with an unclear antigenic 
stimulation of keratinocytes, and induce the 
activation of T-lymphocytes, the release of 
cytokines [including tumor necrosis factor-
alpha (TNF-α) and leukocyte chemotaxis].2 
Since the cause of the disease is unclear, 
many drugs have been evaluated in an 
attempt to relieve the symptoms. A treatment 
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is multidimensional and varies according to 
the predisposing factors. In all the cases, 
management is symptomatic with attempts to 
reduce inflammation and pain of the aphthae 
using topical or systemic treatments.2 The 
choice of drug depends on the severity of the 
disease, the number of ulcers, their location 
and duration and the magnitude of pain.4 
The use of systemic corticosteroids and 
immunomodulating agents has been the 
mainstay of the treatment for recurrent 
aphthous ulcers (RAU).5 Corticosteroids are 
the first choice systemic treatment and 
immune modulators may be useful as the 
second line treatment.2 One of the most 
effective systemic immunomodulators to be 
used in cases of RAU is levamisole.3 
Steroids have been shown to provide 
symptomatic relief, whereas levamisole 
seems to provide symptomatic relief and 
alter the disease course.6 It was found that in 
patients with RAS, the immune system’s 
function becomes disrupted in response to 
some types of trigger factors. Both types of 
the immune response, natural and acquired 
(humoral and cellular), may become 
disturbed in patients with RAS, which is 
manifested with neutrophil reactivation and 
hyper-reactivity, elevated concentration of 
the complement ingredients and cytokines, 
increased number of natural killer (NK) cells 
and B-lymphocytes, and disrupted 
CD4/CD8 ratio.1 
One of the agents used for systemic 
treatment of RAS is levamisole because it 
has a wide variety of immunological effects. 
Previously, it was used as an anti-
helminthic drug. It can provide the normal 
phagocytic activity of macrophages and 
neutrophils, regulate T-cell activity, 
modulate the activity of human interferons 
(IFNs), and the serum levels of interleukin 
(IL-6) and IL-8. In the cases of RAU, it helps 
in normalization of CD4+/CD8+ cell ratio 
and increased level of serum 
immunoglobulin A (IgA) and IgM.3 
This drug has commonly been used as 
monotherapy and an adjunct to treatment in 
a variety of diseases by gastroenterologists 
and dermatologists due to its wide range of 
immunomodulatory actions.4 Many studies 
have done to evaluate the effect of levamisole 
in the treatment of RAS and reported varied 
results with different success rates.7-12 
The present review was conducted to assess 
the effect of levamisole on aphthous lesions via 
a systematic and meta-analysis approach. 
Methods 
Search methodology and study selection 
Our clinical question included four elements: 
population, intervention, comparison, and 
treatment outcomes. This research was 
designed to answer the question whether 
levamisole could be effective in improving 
clinical signs of recurrent aphthous patients 
or not. An electronic search of the PubMed, 
Cochrane, and Scopus databases was 
performed covering the period from 1975 to 
2015. The following appropriate Medical 
Subject Heading (MeSH) terms for search 
were used: aphthous (aphthae, canker sore, 
periadenitis mucosa), recurrent (recurrence, 
relapse, recrudescences), stomatitis 
(stomatitis, oral mucositis, oromucositis), 
treatment (therapy, therapeutic, 
management), levamisole, and combination 
of these terms by the conjunctive operator 
AND and OR (Tables 1 and 2). A hand search 
as well as reference section of each relevant 
article was accomplished. Text files of the 
searched data from the above-mentioned 
databases were imported into the EndNote 
X7.1 for Windows & Mac, Reference 
management. (Thomson Reuters) software.13 
Then, after excluding duplicate records, 2365 
records remained. Exclusion of the irrelevant 
articles was performed in the three steps of 
title, summary and the main text, and 29 
articles remained at the end of this step. The 
full texts of all the related studies were 
evaluated by two authors separately. If there 
was any disagreement between these two 
reviewers, agreement was achieved by 
consulting with the third reviewer/ 
epidemiologist and statistical advisor.  
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Table 1. Description of trials 
Author Year 
Sample size Number of improvement 
Index of improvement Side effect Dosage 
Total Levamisole Placebo Levamisole Placebo 
Lehner et al.
19 
1976 47 26 21 21 6 Number of ulcers 
Duration of ulcers 
Nausea, Influenza 50 mg tid 
2 days/week 
Weekly 
van De Heyning
15 
1978 13 7 6 6 1 Number of ulcers 
Duration of ulcers 
Pain of ulcers 
Frequency of ulcers 
No side effect 150 mg 
3 days/week 
Every other week 
de Cree et al.
17 
1978 18 9 9 7 2 Duration of ulcers 
Pain of ulcers 
Frequency of ulcers 
Headache, Nausea 150 mg 
3 days/week 
Interval of 2 weeks 
Olson and 
Silverman
18 
1978 48 23 25 15 7 Duration of ulcers 
Pain of ulcers 
Frequency of ulcers 
Dysgeusia, Hyperosmia, 
Headache 
150 mg 
3 days/week 
Weekly 
Miller et al.
20 
1978 20 10 10 9 3 Number of ulcers 
Duration of ulcers 
Nausea/diarrhea, 
Dysgeusia, Sleeplessness 
150 mg 
3 days/week 
Every other week 
Kaplan et al.
14 
1978 65 34 31 19 5 Number of ulcers 
Duration of ulcers 
Pain of ulcers 
Frequency of ulcers 
Dysgeusia, Hyperosmia, 
Headache, 
Nausea/vomiting 
150 mg 
3 days/week 
Every other week 
Drinnan and 
Fischman
16 
1978 30 15 15 6 5 Number of ulcers 
Duration of ulcers 
Pain of ulcers 
Frequency of ulcers 
Cacogeusia, Nausea 150 mg 
3 days/week 
Every other week 
Weckx et al.
21 
2009 25 15 10 7 7 Number of ulcers 
Duration of ulcers 
Size of ulcers 
No side effect 150 mg 
3 days/week 
Every other week 
Sharda et al.
6 
2014 30 20 10 12 2 Number of ulcers 
Duration of ulcers 
Pain of ulcers 
Frequency of ulcers 
Size of ulcers 
No side effect 150 mg 
3 days/week 
Weekly for 3 weeks 
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Table 2. The Medical Subject Heading ‎(MeSH) terms and their synonyms 
Levamisole Treatment Aphthous Recurrent Stomatitis 
Tetramisole Therapy Aphthae Recurrence Mucositis 
Levamisole Therapeutic Canker sore Relapse Oromucositis 
Decaris Management Sore canker Recrudescences Stomatitides 
Dekaris  Ulcer, aphthous   
Levamisole hydrochloride  Periadenitis mucosa   
 
The quality evaluation of articles was 
performed using Critical Appraisal Skills 
Program (CASP) according to the Public Health 
Resource Unit (PHRU) (England 2006).13 
All the articles were rated according to this 
checklist and the articles with desirable quality 
were determined. Articles rating 6 and more 
were included in the present study. In this step, 
20 articles were excluded and 9 articles6,14-21 
were included in the study. Subsequently, the 
required data were extracted and imported into 
an Excel (version 2007) sheet. The main 
author’s name, publication date of the article, 
quality assessment rating of each study, type of 
study, sampling method, sample size, study 
groups’ assignment, treatment period duration, 
dose of the drug used, age (range, average), 
male and female ratio, the patients’ response to 
the treatment, clinical outcomes, and side 
effects were systematically recorded. 
The review of literature was confined to 
English papers with randomized clinical trial 
studies. The meta-analysis was carried out on 
the clinical outcomes. 
An estimation of each treatment effect was 
reported as odds ratio (OR) index. In fact, OR 
was measured for every study and then 
pooled using a fixed-effect model. The 
investigation of total variation between 
findings of studies (the estimations of 
treatment/intervention effects from final 
studies) was carried out using Cochran’s test 
for heterogeneity and I2 index. This index 
shows what percentage of differences observed 
between the indexes of the study are due to the 
heterogeneity between the studies. 
The Cochrane guidelines for classification 
of this index are as follows: 
Cochrane Handbook 2008 categories: 
 0-40%: might not be important 
 30-60%: moderate heterogeneity 
 50-90%: substantial heterogeneity  
 75-100%: considerable heterogeneity. 
Results 
Initially, 3837 articles were found using the 
electronic search and hand search. Repetitive 
2365 articles were omitted. Based on the title, 
abstract and full text 1443 irrelevant articles 
were discarded, leaving 29 studies (Figure 1).  
 
 
Figure 1. Flow diagram of studies 
Total searched articles (n = 3837) 
Reduplicative articles (n = 2365) 
 
Excluding irrelevant articles in 3 steps 
1. based on the title (n = 1254) 
2. based on the abstract (n = 171) 
3. based on the full text (n = 18) 
 
Remaining articles (n = 29) 
a) Not being published in English (n = 7) 
b) Cross-sectional studies (n = 3) 
c) Case-control studies (n = 3) 
d) Case report studies (n = 2) 
 Remaining articles (n = 14) 
Excluding due to obtaining low score in 
accreditation (n = 2)  
Excluding due to not presenting qualified 
outcome (n = 3) 
 Studies included in systematic review (n = 9) 
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Table 3. The combination of key words 
Levamisole and treatment Treatment and recurrent and aphthous 
Levamisole and aphthous Treatment and recurrent and stomatitis 
Levamisole and recurrent and aphthous Treatment and stomatitis 
Levamisole and recurrent and stomatitis Treatment and recurrent and aphthous and stomatitis 
Levamisole and stomatitis Levamisole and recurrent and aphthous and stomatitis 
Treatment and aphthous Levamisole and treatment and recurrent and aphthous and stomatitis 
 
 
Figure 2. The overall odds ratio (OR) in a fixed model 
 
Two case reports, 3 case-control, 3 cross-
sectional, and 7 non-English articles were 
separated. Quality assessment of the 14 studies 
was executed according to the PHRU and 9 
articles had suitable qualifications (Score 6 or 
more) for the accomplishment of systematic 
review and meta-analysis. Table 3 shows the 
basic information of these 9 studies. 
Meta-analysis results of levamisole are 
presented in figure 2. The chance of 
improvement in patients taking levamisole 
was 6 [OR = 5.67, 95% confidence interval 
(CI)] times more than in patients not taking 
this drug, and the difference was significant 
(P = 0.001). 
In this study, heterogeneity of chi-squared 
results was Q = 20.732 on 8 degrees of 
freedom (P = 0.008), which was significant at 
5% level of significance. Therefore, the study 
results were heterogenic. 
Discussion 
This study was performed based on 
Cochrane systematic review and meta-
analysis. The research question was designed 
to answer whether levamisole is effective in 
improving clinical signs and symptoms of 
RAS or not. According to the results of meta-
analysis, levamisole improves the clinical 
signs of RAS. RAS is a common disease and 
despite many research studies in this field, 
the etiology of this condition is unknown and 
there is no definitive treatment for it.2 
As the mentioned earlier, the use of 
OR 
.069151 611.797 
 Combined           2.6    12.4 
 Sharda et al.6 (2014)       1.1     19.8 
 Weckx et al.21 ‎( 2009)          0.1     1.5 
 Drinna et al.16 (1978)          0.4     4.6 
 Kaplan et al.14 (1978)         2.4     17.6 
 Miller et al.20 (1978)           2.6     166.8 
 Olson and Silverman18    (1978)           1.7    13.4 
 de Cree et al.17 (1978)          3.1    249.4      
van de Heyning15 (1977)     2.4   376.7 
 Lehner et al.19 (1976)        7.0 L   125.6U    90%CI 
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systemic corticosteroids and 
immunomodulating agents has been the 
mainstay of treatment for RAU.5 One of the 
most effective systemic immunomodulators 
to be used in cases of RAU is levamisole.3 
The exact mode of action of levamisole 
remains unclear. Levamisole reportedly 
decreases the frequency, duration and 
number of oral ulcers. Levamisole has been 
found to immunomodulate T-cell-mediated 
immunity. Normalization of the decreased 
CD4+/CD8+ cell ratio and increased serum 
levels of IgA and IgM has been found in RAU 
patients after levamisole treatment.3 The 
serum TNF-α level may be associated with 
the severity of RAS. It has been concluded 
that levamisole can modulate serum TNF-α 
levels in RAS patients.22 IL-6 and IL-8 are 
pro-inflammatory cytokines that affect 
cellular and humoral immunities and 
levamisole can modulate the serum level of 
these cytokines.3,23 
This drug has proven to increase 
hemoglobin concentration of the patient along 
with regulating immune system of RAS 
patients.4 Based on evidence available, it 
seems that levamisole could be effective in the 
treatment of RAS.2-5,22,23 Many studies have 
evaluated this subject. Outcomes of some of 
these studies confirm the effect of levamisole 
on improving clinical signs of aphthous 
lesions including reduction of frequency, 
number, duration, size, and pain of ulcers.6,14-21 
We assess the results of 9 selected articles 
in different dimensions. 
Levamisole and frequency of ulcers 
Six articles showed that levamisole could 
reduce the frequency of aphthous periods 
and increase the interval of episodes.6,14-18 
Levamisole and duration of ulcers 
All the 9 articles supported the effect of 
levamisole on decreasing duration of ulcers 
in the mouth and accelerating recovery of 
ulcers.6,14-21 
Levamisole and the number of ulcers 
Seven studies demonstrated a decrease in the 
number of lesions in different sites by 
levamisole.6,14-16,19-21 
Levamisole and size of ulcers 
In two investigations, the diameter of ulcers 
were measured and a reduction in ulcer sizes 
was noted after taking levamisole.6,21 
Levamisole and pain of ulcers 
The results of six trials confirmed the effect of 
levamisole on decreasing pain of aphthous 
ulcers.6,14-18 
Levamisole and types of aphthous lesions 
Two studies described their results based on 
the classification of aphthous lesions 
including minor, major, and herpetic form. 
Olson and Silverman18 reported that 
levamisole had more effects on improvement 
of minor aphthous than major aphthous 
ulcers, whereas Lehner et al.’s study19 
showed that the efficacy of levamisole in 
recovery of major aphthous ulcers was more 
significant than minor aphthous ulcers. 
Method of administration 
Five methods had been used in the articles 
reviewed. 
A. 150 mg daily for 3 consecutive 
days/weeks18 
B. 150 mg for 3 consecutive days every 
other week14-16,20,21 
C. 50 mg 3 times daily for 2 consecutive 
days every week19 
D. 150 mg three times daily for 3 
consecutive days/weeks6 
E. 150 mg daily for 3 consecutive 
days/weeks with an interval of 2 weeks17 
The duration of trials and follow-up 
periods of patients were different in different 
studies, from 2 to 6 months but all of them 
reported that no clinical changes were seen 1 
month after initiation of treatment. Differences 
in methods of administration and trial 
protocols in a wide range of duration resulted 
in differences between the results of studies. 
Adverse effects of levamisole are mild and 
infrequent and include rash, nausea, 
abdominal cramps, alopecia, arthralgia, 
hyperosmia, dysgeusia and a flu-like 
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syndrome and rarely agranulocytosis.3,4 The 
most common adverse effects of levamisole 
in the mentioned studies were headache, 
nausea, dysgeusia, and hyperosmia.14,16-20 
Overall, 6 articles confirmed the efficacy of 
levamisole in improving clinical signs of 
RAS,6,14,15,17-19 while 3 articles did not support 
the influence of levamisole for recovery of 
clinical signs of aphthous stomatitis.16,20,21 
In general, the study results show that 
studies were heterogenic. The heterogeneity 
was attributed to differences in methods of 
administration of levamisole (differences in 
doses and duration), carrying out the trials in 
different years and lack of a standard index 
for improvement between different studies. 
Moreover, this review showed that there is a 
time lag between the studies. Most studies 
conducted in the years 1976-1978 and only 
two studies recently conducted (2009 and 
2014).6,21 However, despite the effectiveness 
of levamisole in the improving of clinical 
signs of RAS that in most older studies 
referenced,14,15,17-19 the reason of this time lag 
is not specified. Therefore, further studies are 
necessary on this topic.  
Limitations 
The most important factor was the number of 
appropriate studies carried out in this 
context; therefore, further studies are 
necessary on this topic. Since levamisole was 
administered at different doses using 
different protocols in different studies, it is 
difficult to evaluate discrepancies between 
studies with differences in their data. It is 
suggested that future studies use 
standardized variables and similar conditions 
including evaluation of size, number, 
duration, frequency and pain of ulcers, to 
facilitate comparisons between the results of 
different studies. The types of aphthous 
ulcers (minor, major and herpetic form) 
should be considered for more accurate 
assessment of the influence of levamisole. 
Administration of an equal dose of levamisole 
with the same prescription order and similar 
period of follow-up make it possible to 
compare the results of different studies. 
Conclusion 
Many studies have been undertaken to find 
an appropriate treatment for RAS and 
numerous topical and systemic interventions 
have been used.24,25 Administration of 
levamisole is one of the systemic 
interventions for the treatment of RAS 
because of its immunomodulatory action. 
The results of this study showed that the 
chance of improvement in patients taking 
levamisole was 6 times more than that in 
patients not taking it. Although several 
studies supported its efficacy, further studies 
are necessary in this field. 
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